June 15, 2015
Adapt Pharma rolls submision to NDA for naloxone-based nasal spray
The National Institute on Drug Abuse (NIDA) has announced that Adapt Pharma Limited, a partner of Lightlake Therapeutics Inc., has started a rolling…
Pharmaceuticals, Biotechnology and Life Sciences
The National Institute on Drug Abuse (NIDA) has announced that Adapt Pharma Limited, a partner of Lightlake Therapeutics Inc., has started a rolling…
Cosentyx (secukinumab) met the primary endpoints of superiority compared to placebo in patients with difficult-to-treat psoriasis of the nails, palms…
Novartis announced data that show majority of patients with polycythemia vera treated with Jakavi achieved long-term disease control. The company said…
Novartis reports new analysis showing Xolair® improving quality of life by 78% for chronic spontaneous urticaria patients New analysis from…